VivoSeq
Infectious Disease

Trypanosomiasis

9

Pipeline Programs↗

0

Active Trials↗

6

Companies Involved↗

Trypanosomiasis is an early-stage landscape with 9 programs across 6 companies. The most active players are Pfizer, Immtech Pharmaceuticals, Inc, Oncozyme Pharma Inc.. 4 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1I

Immtech Pharmaceuticals, Inc

1 program

Phase 2O

Oncozyme Pharma Inc.

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 3K

Knight Therapeutics (USA) Inc

1 program

ApprovedF

Fresenius Kabi Oncology Ltd.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Unknown status1 · 33%

Clinical Trials

Trial Activity

A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Completed·IImmtech Pharmaceuticals, Inc·Phase 2·NCT00802594·30 enrolled
Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Completed·IImmtech Pharmaceuticals, Inc·Phase 2·NCT00803933·111 enrolled
CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)
Unknown status·UUniversidad Autónoma de Bucaramanga·Phase 2/3·NCT02369978·500 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)